Unknown

Dataset Information

0

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.


ABSTRACT: The development of new treatments for older patients with acute myeloid leukemia is an active area, but has met with limited success. Vosaroxin, a quinolone-derived intercalating agent has several properties that could prove beneficial. Initial clinical studies showed it to be well-tolerated in older patients with relapsed/refractory disease. In vitro data suggested synergy with cytarabine (Ara-C). To evaluate vosaroxin, we performed 2 randomized comparisons within the "Pick a Winner" program. A total of 104 patients were randomized to vosaroxin vs low-dose Ara-C (LDAC) and 104 to vosaroxin + LDAC vs LDAC. When comparing vosaroxin with LDAC, neither response rate (complete recovery [CR]/complete recovery with incomplete count recovery [CRi], 26% vs 30%; odds ratio [OR], 1.16 (0.49-2.72); P = .7) nor 12-month survival (12% vs 31%; hazard ratio [HR], 1.94 [1.26-3.00]; P = .003) showed benefit for vosaroxin. Likewise, in the vosaroxin + LDAC vs LDAC comparison, neither response rate (CR/CRi, 38% vs 34%; OR, 0.83 [0.37-1.84]; P = .6) nor survival (33% vs 37%; HR, 1.30 [0.81-2.07]; P = .3) was improved. A major reason for this lack of benefit was excess early mortality in the vosaroxin + LDAC arm, most obviously in the second month following randomization. At its first interim analysis, the Data Monitoring and Ethics Committee recommended closure of the vosaroxin-containing trial arms because a clinically relevant benefit was unlikely.

SUBMITTER: Dennis M 

PROVIDER: S-EPMC4536889 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis Mike M   Russell Nigel N   Hills Robert K RK   Hemmaway Claire C   Panoskaltsis Nicki N   McMullin Mary-Frances MF   Kjeldsen Lars L   Dignum Helen H   Thomas Ian F IF   Clark Richard E RE   Milligan Don D   Burnett Alan K AK  

Blood 20150324 19


The development of new treatments for older patients with acute myeloid leukemia is an active area, but has met with limited success. Vosaroxin, a quinolone-derived intercalating agent has several properties that could prove beneficial. Initial clinical studies showed it to be well-tolerated in older patients with relapsed/refractory disease. In vitro data suggested synergy with cytarabine (Ara-C). To evaluate vosaroxin, we performed 2 randomized comparisons within the "Pick a Winner" program. A  ...[more]

Similar Datasets

| S-EPMC8714727 | biostudies-literature
| S-EPMC5144553 | biostudies-literature
| S-EPMC9631625 | biostudies-literature
| S-EPMC8008421 | biostudies-literature
| S-EPMC8085967 | biostudies-literature
| S-EPMC5622855 | biostudies-literature
| S-EPMC4354261 | biostudies-literature
| S-EPMC7718665 | biostudies-literature
| S-EPMC6219441 | biostudies-literature